Arcellx (NASDAQ:ACLX) Stock Price Up 5.1% After Analyst Upgrade
Arcellx, Inc. (NASDAQ:ACLX – Get Free Report)’s share price rose 5.1% on Wednesday after UBS Group raised their price target on the stock from $106.00 to $114.00. UBS Group currently has a buy rating ...
STAT21h
Arcellx won the battle of BCMA CAR-T therapies
I just returned from San Diego and the annual meeting of the American Society of Hematology, where Arcellx won the battle of ...
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
Arcellx stock reversed lower Monday on positive results for its rival to Legend Biotech's multiple myeloma treatment, ...
Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients
Arcellx, Inc. (NASDAQ:ACLX) revealed new data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel ...
HC Wainwright Reiterates Buy Rating for Arcellx (NASDAQ:ACLX)
Arcellx (NASDAQ:ACLX – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to ...
STAT2d
An entertaining biotech fight, and a ‘nail in the coffin’ for transplants in mantle cell lymphoma
The feud between Arcellx and Legend Biotech over their anti-BCMA CAR-T therapies for multiple myeloma is getting extra spicy ...
Arcellx price target raised to $114 from $106 at UBS
UBS analyst Ashwani Verma raised the firm’s price target on Arcellx (ACLX) to $114 from $106 and keeps a Buy rating on the shares. UBS believes ...
Arcellx Inc (ACLX) Gets a Buy from Truist Financial
In a report released today, Richard Newitter from Truist Financial maintained a Buy rating on Arcellx Inc (ACLX – Research Report). The ...
BioSpace1d
J&J, Legend Shrug Off Carvykti’s Challengers With New Phase III Data
With nearly 90% of patients showing no detectable cancer cells after treatment, J&J and Legend’s Carvykti could stave off ...
In-Depth Examination Of 14 Analyst Recommendations For Arcellx
Analysts have recently evaluated Arcellx and provided 12-month price targets. The average target is $107.71, accompanied by a ...
Business Wire1mon
Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition ...
--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable ...